{"id":53504,"date":"2022-09-23T18:11:50","date_gmt":"2022-09-23T22:11:50","guid":{"rendered":"https:\/\/www.singlecare.com\/blog\/?p=53504"},"modified":"2024-09-10T12:32:08","modified_gmt":"2024-09-10T16:32:08","slug":"janumet-alternatives","status":"publish","type":"post","link":"https:\/\/www.singlecare.com\/blog\/janumet-alternatives\/","title":{"rendered":"Janumet alternatives: What can I take instead of Janumet?"},"content":{"rendered":"

Compare Janumet alternatives<\/a> | <\/span>Jardiance<\/span><\/a> | Rybelsus<\/a> | <\/span>Glipizide<\/span><\/a> | Xigduo XR<\/a> | Steglujan<\/a> | Natural alternatives<\/a> | How to switch meds<\/a><\/span><\/p>\n

Effectively treating <\/span>Type 2 diabetes mellitus<\/span><\/a> often requires multiple medications, and <\/span>Janumet<\/span><\/a> (<\/span>sitagliptin<\/span>\/<\/span>metformin<\/span>) is a combination product that can reduce your pill and <\/span>copay<\/span> burden. The convenience comes with some negative trade-offs though, that may have you looking for a different approach. <\/span>Janumet<\/span> contains <\/span>sitagliptin<\/span>, a pricey <\/span>dipeptidyl peptidase-4<\/span> (DPP-4) <\/span>inhibitor<\/span> that has no available generic, and <\/span>metformin<\/span>, a <\/span>biguanide<\/span><\/a> that is notorious for causing diarrhea. If you are experiencing either an adverse effect on your bowel or your wallet, you should read on to discover what other options exist.<\/span><\/p>\n

RELATED: <\/b>Janumet side effects and how to avoid them<\/b><\/a><\/p>\n

What can I take in place of <\/span>Janumet<\/span>?<\/span><\/h2>\n

Unfortunately, <\/span>metformin<\/span>\u2019s effectiveness may not be enough to meet your goals for glucose control, and at that point, a host of options exists to add to it. The <\/span>DPP-4 inhibitor<\/span> Januvia<\/span> (<\/span>sitagliptin<\/span>) may be chosen based on the low risk of <\/span>hypoglycemia<\/span> and low incidence of <\/span>side effects<\/span> in general. By bringing <\/span>metformin<\/span> and <\/span>sitagliptin<\/span> together in one pill, <\/span>Janumet<\/span> offers you a cost and convenience advantage. Your insurance <\/span>formulary<\/span><\/a> may favor a different <\/span>DPP-4 inhibitor<\/span>, such as <\/span>Tradjenta<\/span>, <\/span>Onglyza<\/span>, or <\/span>Nesina<\/span>, all of which are also available in combination tablets with <\/span>metformin<\/span> (<\/span>Jentadueto<\/span>, <\/span>Kombiglyze<\/span> XR, and <\/span>Kazano<\/span>, respectively).<\/span><\/p>\n

Treatment options for <\/span>Type 2 diabetes<\/span><\/a> abound, so if <\/span>DPP-4 inhibitors<\/span> are not meeting your needs, you have plenty of other <\/span>drug classes<\/span> to choose from. <\/span>Glucagon<\/span>-like peptide-1 (<\/span>GLP-1<\/span>) <\/span>agonists<\/span><\/a> and <\/span>sodium-glucose cotransporter 2 (SGLT2) <\/span>inhibitors<\/span><\/a> are relatively new categories that are often favored due to their strong efficacy and additional benefits. Mounjaro is a novel agent that acts as an <\/span>agonist<\/span> to both the <\/span>GLP-1<\/span> and glucose-dependent insulinotropic polypeptide (GIP) receptors. Older and cheaper categories of <\/span>diabetes medications<\/span> include the <\/span>sulfonylurea<\/span><\/a>, <\/span>alpha-glucosidase <\/span>inhibitor<\/span><\/a>, and <\/span>thiazolidinedione<\/span><\/a> classes, each still having a role in certain circumstances. Finally, the many forms of <\/span>insulin<\/span><\/a> can be a reliable choice, albeit one that is usually selected when others have failed. You will certainly want to know more specifics when comparing your options.<\/span><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Compare Janumet alternatives<\/span><\/h2>\n<\/th>\n<\/tr>\n<\/thead>\n

Drug name<\/b><\/td>\nUses<\/b><\/td>\nDosage<\/b><\/td>\nCoupons<\/b><\/td>\n<\/tr>\n
Janumet (sitagliptin\/metformin)<\/td>\nType 2 diabetes mellitus<\/td>\n50 mg\/500 mg to 50 mg\/1000 mg twice daily<\/td>\nJanumet coupons<\/a><\/td>\n<\/tr>\n
Janumet XR (sitagliptin\/metformin extended-release)<\/td>\nType 2 diabetes mellitus<\/td>\n100 mg\/1000 mg once daily to 50 mg\/1000 mg twice daily<\/td>\nJanumet XR coupons<\/a><\/td>\n<\/tr>\n
Metformin<\/td>\nType 2 diabetes mellitus, polycystic ovarian syndrome (off-label<\/a>)<\/td>\n500-1000 mg twice daily<\/td>\nMetformin coupons<\/a><\/td>\n<\/tr>\n
Januvia (sitagliptin)<\/td>\nType 2 diabetes mellitus<\/td>\n100 mg once daily<\/td>\nJanuvia coupons<\/a><\/td>\n<\/tr>\n
Steglujan (ertugliflozin\/sitagliptin)<\/td>\nType 2 diabetes mellitus<\/td>\n5 mg\/100 mg to 15 mg\/100 mg once daily<\/td>\nSteglujan coupons<\/a><\/td>\n<\/tr>\n
Xigduo XR (dapagliflozin\/metformin extended-release [ER])<\/td>\nType 2 diabetes mellitus<\/td>\n1-2 tablets every morning (2.5-10 mg of dapagliflozin with 500-1000 mg of extended-release metformin per tablet)<\/td>\nXigduo XR coupons<\/a><\/td>\n<\/tr>\n
Trulicity (dulaglutide)<\/td>\nType 2 diabetes mellitus, cardiovascular event risk reduction in those with Type 2 diabetes and cardiovascular disease or multiple risk factors<\/td>\n0.75-4.5 mg subcutaneous (under the skin) injection once weekly<\/td>\nTrulicity coupons<\/a><\/td>\n<\/tr>\n
Ozempic (semaglutide)<\/td>\nType 2 diabetes mellitus, cardiovascular event risk reduction in those with Type 2 diabetes and cardiovascular disease<\/td>\n0.5-1 mg subcutaneous injection once weekly<\/td>\nOzempic coupons<\/a><\/td>\n<\/tr>\n
Rybelsus (semaglutide)<\/td>\nType 2 diabetes mellitus<\/td>\n7-14 mg once daily<\/td>\nRybelsus coupons<\/a><\/td>\n<\/tr>\n
Victoza (liraglutide)<\/td>\nType 2 diabetes mellitus, cardiovascular event risk reduction in those with Type 2 diabetes and cardiovascular disease<\/td>\n1.2-1.8 mg subcutaneous injection once daily<\/td>\nVictoza coupons<\/a><\/td>\n<\/tr>\n
Mounjaro (tirzepatide)<\/td>\nType 2 diabetes mellitus<\/td>\n5-15 mg subcutaneous injection once weekly<\/td>\nMounjaro coupons<\/a><\/td>\n<\/tr>\n
Farxiga (dapagliflozin)<\/td>\nType 2 diabetes mellitus, heart failure risk reduction in Type 2 diabetes mellitus with heart disease or multiple cardiovascular risk factors, heart failure risk reduction in those with reduced cardiac ejection fractions, heart failure and kidney disease progression risk reduction in those with chronic renal disease<\/td>\n5-10 mg once daily<\/td>\nFarxiga coupons<\/a><\/td>\n<\/tr>\n
Jardiance (empagliflozin)<\/td>\nType 2 diabetes mellitus, cardiovascular event risk reduction in Type 2 diabetes mellitus, heart failure risk reduction in those with reduced cardiac ejection fractions<\/td>\n10-25 mg once daily<\/td>\nJardiance coupons<\/a><\/td>\n<\/tr>\n
Invokana (canagliflozin)<\/td>\nType 2 diabetes mellitus, cardiovascular event risk reduction in Type 2 diabetes mellitus with cardiovascular disease, kidney disease progression risk reduction and cardiovascular event risk reduction in those with Type 2 diabetes mellitus and nephropathy and albuminuria >300 mg\/day<\/td>\n100-300 mg once daily<\/td>\nInvokana coupons<\/a><\/td>\n<\/tr>\n
Glipizide<\/td>\nType 2 diabetes mellitus<\/td>\n2.5-20 mg twice daily<\/td>\nGlipizide coupons<\/a><\/td>\n<\/tr>\n
Lantus Solostar (insulin glargine)<\/td>\nType 2 diabetes mellitus, Type 1 diabetes mellitus<\/td>\nIndividualized dose injected subcutaneously once daily<\/td>\nLantus Solostar coupons<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Other alternatives to <\/span>Janumet<\/span><\/h3>\n

Metformin<\/span><\/a> is typically the <\/span>first agent chosen<\/span><\/a> to treat <\/span>Type 2 diabetes mellitus<\/span>. The potential to <\/span>slow the progression of diabetes<\/span><\/a> and avoid <\/span>weight gain<\/span> and <\/span>hypoglycemia<\/span> (<\/span>low blood sugar<\/span>) makes a strong argument for its use in most cases. Extended or slow-release <\/span>metformin<\/span> products can help to avoid the diarrhea <\/span>side effect<\/span> that afflicts many users.<\/span><\/p>\n